The effects of tamoxifen on immunity.
Tamoxifen is a widely known anti-estrogen which has been employed in adjuvant treatment of early-stage, estrogen-sensitive breast cancer for over 20 years. Less well known are the effects of tamoxifen on immune function, which we discuss here. We review the growing body of evidence which demonstrates immunomodulatory effects of tamoxifen, including in vitro and in vivo studies as well as observations made in breast cancer patients treated with tamoxifen. Taken together these studies suggest that tamoxifen is capable of inducing a shift from cellular (T-helper 1) to humoral (T-helper 2) immunity. Interestingly, the immunomodulatory effects of tamoxifen appear to be independent of the estrogen-receptor and may be mediated through the multidrug resistance gene product, Permeability-glycoprotein, for which a role in immunity has recently emerged. We furthermore discuss the clinical implications of the immunomodulatory effects of tamoxifen which are twofold. First, tamoxifen may be useful in the treatment of immune-mediated disorders, particularly of those arising from aberrant T-helper 1 cell activity, including allograft rejection, Crohn's disease, and Th1-mediated autoimmune conditions such as diabetes mellitus, scleroderma, and multiple sclerosis. Second, given that cellular T-helper 1 immunity is targeted against cancer cells, the tamoxifen-induced shift away from cellular immunity represents a significant step in fostering a cancerogenic environment. This may limit the anti-cancer effects of tamoxifen and thus explain why tamoxifen is inferior compared to other anti-estrogens in preventing disease recurrence in early-stage breast tumors.
Behjati
S
S
Academic Clinical Fellow, UCL Institute of Child Health, London, UK.
Frank
M H
MH
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D001943:Breast Neoplasms / Q000188:drug therapy; D004965:Estrogen Antagonists / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D006377:T-Lymphocytes, Helper-Inducer / Q000187:drug effects* / Q000276:immunology; D013629:Tamoxifen / Q000494:pharmacology*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D004965:Estrogen Antagonists; D007155:Immunologic Factors; D013629:Tamoxifen
J Rheumatol. 1994 Dec;21(12):2231-8
7699622
Annu Rev Biochem. 1993;62:385-427
8102521
J Clin Immunol. 2001 Nov;21(6):420-30
11811787
Am J Transplant. 2006 Dec;6(12):2884-93
17083370
N Engl J Med. 2005 Dec 29;353(26):2747-57
16382061
Cancer Treat Rep. 1986 Mar;70(3):381-2
3955549
J Immunol. 2002 Feb 15;168(4):1572-8
11823484
Br J Cancer. 1995 Feb;71(2):294-9
7841043
Clin Cancer Res. 2006 Sep 1;12(17):5010-3
16951214
Eur J Pharm Sci. 2000 Oct;11(4):265-83
11033070
Scand J Immunol. 2000 Oct;52(4):393-400
11013011
Br J Pharmacol. 2006 Jan;147 Suppl 1:S269-76
16402113
Cancer Immunol Immunother. 1993 Aug;37(3):209-12
8334683
Eur J Immunol. 2004 Dec;34(12):3702-12
15517615
Rheumatology (Oxford). 2001 Feb;40(2):185-91
11257155
Pharmacol Rev. 2001 Mar;53(1):25-71
11171938
Immunology. 2000 May;100(1):110-8
10809966
Breast Cancer Res Treat. 1988 Sep;12(1):75-9
3196888
J Immunol. 2001 Feb 15;166(4):2451-9
11160305
Curr Drug Targets. 2003 Aug;4(6):469-76
12866661
Blood. 2000 May 1;95(9):2875-82
10779434
Nat Med. 1996 Apr;2(4):381-5
8597938
Ann Rheum Dis. 2003 Apr;62(4):341-6
12634234
Biochem Pharmacol. 1994 Jul 19;48(2):287-92
7914405
Lancet. 2005 Jan 1-7;365(9453):60-2
15639680
Am J Hematol. 1995 Aug;49(4):323-35
7639278
Lancet. 1998 May 16;351(9114):1451-67
9605801
J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):350-3
18406603
Arch Dermatol. 2006 Jan;142(1):70-2
16415389
Glia. 2009 May;57(7):777-90
19031437
Scott Med J. 2002 Feb;47(1):12-3
11980291